Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Net Income (2018 - 2025)

Historic Net Income for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$13.4 million.

  • Arcturus Therapeutics Holdings' Net Income fell 9481.38% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 656.73%. This contributed to the annual value of -$80.9 million for FY2024, which is 17229.94% down from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Net Income stood at -$13.4 million for Q3 2025, which was down 9481.38% from -$9.2 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Net Income ranged from a high of $118.6 million in Q4 2022 and a low of -$57.7 million during Q1 2021
  • In the last 5 years, Arcturus Therapeutics Holdings' Net Income had a median value of -$21.6 million in 2022 and averaged -$17.9 million.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Net Income plummeted by 50944.83% in 2021, and later skyrocketed by 41516.0% in 2022.
  • Arcturus Therapeutics Holdings' Net Income (Quarter) stood at -$37.6 million in 2021, then skyrocketed by 415.16% to $118.6 million in 2022, then crashed by 109.84% to -$11.7 million in 2023, then tumbled by 156.89% to -$30.0 million in 2024, then skyrocketed by 55.18% to -$13.4 million in 2025.
  • Its Net Income stands at -$13.4 million for Q3 2025, versus -$9.2 million for Q2 2025 and -$14.1 million for Q1 2025.